论文部分内容阅读
Background: Taxanes are a family of major chemotherapeutic agents that have anti-neoplastic effects against a wide spectrum of human cancers.PRR13 is a proline-rich protein 13, also named TXR1-Taxo1 Resistance Gene 1, and could reduced taxane-induced cell death.A number of strategies have been used to improve the efficacy of the DNA vaccine for the treatment of tumors.These strategies, ranging from activating CD4+ T cell, manipulating antigen presentation and/or processing to anti-micrangium (TSP-1), focus on one certain aspect in the functioning of the vaccine.Therefore, their combination is necessary for rational DNA vaccines design by synergizing different regimens and over coming the limitations of each strategy.Methods: A full length DNA fragment of TXR1 (447bp) was obtained by PCR from MCF-7 cell lines and inserted into the sequence between the luminal and transmembrane domain of human lysosome-associated membrane protein-1 (LAMP-1) cDNA for the construction of a novel DNA vaccine, named pVAX-L/TXR1.Other two plasmids were constructed respectively, i.e.pVAX-TXR1 and pVAX-L.pVAX vector with the Food and Drug Administration (FDA) document was as a negative control.Four groups Balb/c mice were immunized subcutaneously at the base of the tail with four different DNA plasmids.The mice were boosted twice every 3 weeks with the same plasmid.Blood samples were collected by tail vein bleeding of the immunized mice 2 weeks after each immunization.Specific antibody production in serum was detected by ELISA for humoral immune response.At the same time, TXR1 over-lapping peptide-specific IFN-γ secretion was measured by ELISpot for cellular immune response.Results: ELISA result showed that antibody titer in immunized serum of both pVAX-L/TXR1 and pVAX-TXR1 groups were much higher than other two groups.And pVAX-L/TXR1 group had a greater response than pVAX-TXR1 group.ELISpot analyses indicated that pVAX-L/TXR1 significantly elicited IFN-γ response than pVAX-PRR13.Whereas, pVAX-LAMP and pVAX induced very low levels, respectively.Conclusions: This study results demonstrated that novel vaccine with TXR1 and LAMP chimera by trafficking target antigen to the MHC class II compartment can remarkably enhance cellular and humoral immune response.